An FDA Form 483 is the list of observations an investigator hands you at the end of an inspection. It is not a Warning Letter, and it is not FDA’s final position that you broke the law. It is the moment when a written response, sent within 15 business days, is most likely to be read before the agency decides whether to escalate.
Shehadeh Giannamore, PLLC represents food, dietary supplement, cosmetic, medical device, and drug companies that receive inspection observations, FDA Warning Letters, and import actions. This article explains what a Form 483 is, how the response clock runs, and what a useful reply contains. It is general information, not legal advice about your inspection.
What an FDA 483 actually is
FDA investigators use Form FDA 483, Inspectional Observations, to write down conditions they observed that, in their judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act or related regulations. The form is issued at the close of the inspection, usually during the closeout meeting with management.
Three limits matter:
- The observations are the investigator’s, not a final agency decision.
- The form lists significant observations. It does not list every discussion item from the inspection, and it is not a certificate that unlisted areas are compliant.
- You are not legally required to answer it. Choosing not to answer is still a decision FDA can weigh when it decides what comes next.
Companies often call these documents “483s FDA” or simply “an FDA 483.” The official name is Form FDA 483.
How a Form 483 becomes a Warning Letter
After the inspection, the investigator writes an Establishment Inspection Report. FDA’s compliance staff then decide whether the observations, taken with your response, support further action. That action is often a Warning Letter. It can also be a regulatory meeting, an import alert, a seizure recommendation, an injunction referral, or, for some drug applications, a complete response or a withheld approval.
FDA’s longstanding practice, restated in its March 2026 draft guidance on drug CGMP Form 483 responses, is straightforward. If the agency receives a response within 15 business days after the Form 483 was issued, it plans to conduct a detailed review of that response before deciding whether to take further action. It will not ordinarily delay a Warning Letter or other action in order to review a response that arrives after that window.
A Warning Letter is a different document. It states FDA’s position that significant violations occurred, it is posted on FDA’s website, and it typically asks for its own written response within 15 business days of receipt. The practical path from inspection to public enforcement looks like this:
- Inspection and closeout meeting.
- Form 483 issued.
- Company response, if any, inside 15 business days.
- FDA review of the Establishment Inspection Report and the response.
- Warning Letter, another enforcement step, or no further action.
A thorough Form 483 response is one of the few chances to keep the matter off FDA’s public Warning Letter page. Once a letter issues, the work shifts to responding to the Warning Letter itself, including corrections FDA can verify and, later, a request for a close-out letter.
Untitled letters sit on a separate track. They address issues FDA treats as less serious than Warning Letter violations, often marketing claims, and they still need a prompt reply. More on that distinction is in the firm’s note on FDA untitled letters.
The FDA 483 response timeline
Count 15 business days from the date the Form 483 was issued. Business days are Monday through Friday, excluding federal holidays under 5 U.S.C. § 6103. In ordinary practice the issue date is day zero and is not one of the 15 days. If FDA later amends the Form 483, the draft drug guidance says the 15 business days may run from the amendment. Confirm the amendment date in writing so the clock is not guessed.
| Event | What to do |
|---|---|
| Closeout meeting | Clarify each observation. Ask which products, lots, dates, and records the investigator relied on. Do not argue every point in the room if you do not yet have the records. |
| Day 0 | Form 483 issued. Start a written record of who owns each observation. |
| Days 1–3 | Preserve records. Stop shipments or quarantine lots if an observation raises a real product-quality or safety question. Notify counsel. |
| Days 1–10 | Root-cause work, interim controls, and drafting. Collect exhibits you will actually attach. |
| By day 15 | Submit one complete response, or a complete response plus a CAPA plan and dates for anything that cannot be finished yet. |
| After day 15 | Updates are still useful, but FDA will not ordinarily hold a Warning Letter to read them. |
Send one response that covers every observation. A string of partial letters is harder for the reviewer to use, and the March 2026 draft guidance tells drug establishments to avoid that approach. If a correction genuinely cannot be finished in 15 business days, say what is already done, what interim control protects product in the meantime, and the date the remaining work will be done. Then send the update on that date.
What to put in the response
Answer the observations in the order FDA listed them. For each one, a reviewer should be able to see the observation, your position, the evidence, and the date of the next step.
Restate the observation briefly. Use FDA’s numbering. Do not rewrite it into something narrower than what was written.
State your position in plain terms. Correct it, partially disagree with the scope, or disagree and explain why. A blanket “we disagree” with no records is not a response. A blanket admission, copied into later litigation or a consumer case, can be worse. Admissions should match the facts you have actually confirmed.
Give the facts and the records. Name the batch, the date, the SOP, and the result. Attach the revised procedure, the training roster, the retest, or the label proof. A promise to “retrain staff” without a date, a curriculum, or an attendance record is the kind of reply FDA has criticized for years.
Separate correction from prevention. Correction fixes the lot, label, record, or batch the investigator saw. Prevention changes the system that allowed it: incoming testing, complaint handling, supplier qualification, data review, or claim approval. FDA is looking for both.
Assess the scope. Say whether you checked other products, lines, sites, and time periods, and what you found. If you have not finished that review, give the date it will finish.
Name an owner and a date. Each open item needs a person and a completion date you can meet. Missed dates in a follow-up are themselves a credibility problem.
Mark confidential material. Responses can be requested under the Freedom of Information Act. Identify trade secrets and confidential commercial information so a later disclosure review has something to work from. Do not assume the whole letter will stay private. Unlike Warning Letters, Form 483s are not routinely posted by FDA, but they are agency records and are often released.
For drug CGMP inspections, FDA’s March 2026 draft guidance also recommends a table of contents, an explanation of product-quality impact, and management responsibility for the quality system. That guidance is draft and is aimed at drug establishments. The same habits, one submission, evidence instead of assurances, and a real CAPA calendar, are what compliance staff look for in food, supplement, cosmetic, and device files as well.
Disagreements, annotations, and the closeout meeting
You can disagree with an observation. Do it with the record the investigator cited, the regulation that actually applies, and the result of any recheck you ran. Scientific or technical disagreements should be specific. “Our process is validated” is not a disagreement. The protocol, the acceptance criteria, and the data are.
FDA’s Investigations Operations Manual has long allowed investigators, in defined circumstances, to add annotations at the closeout, such as a promised correction, a correction already made, or a reported correction that was not verified. An annotation is not a close-out. It does not stop a Warning Letter. Treat it as a note on the form, then prove the correction in the written response.
Use the closeout to understand the observation, not to litigate it. Ask which regulation the investigator believes applies. Ask whether the issue was discussed with your quality unit during the inspection. Correct any factual mistake, such as the wrong product code or the wrong date, before the meeting ends if you can do it from records in the room.
What a weak response looks like
FDA has said for years, in Warning Letters across product categories, that it is not satisfied by promises. Patterns that show up again and again:
- The reply restates the SOP that was already in place when the investigator found it was not followed.
- Training is promised with no roster, no date, and no check that the training changed the practice.
- The company fixes the cited batch and does not look at other batches made the same way.
- The response argues the legal conclusion in the first paragraph and attaches nothing.
- Deadlines are “as soon as possible.”
- A later update contradicts the first letter.
Those replies do not just fail to persuade. They become exhibits in the Warning Letter, which then quotes them.
Who should be involved before you draft
The people who own the records should gather them. The people who will sign the CAPA dates should agree the dates are real. Counsel should see the draft before it goes to FDA, because the letter is a statement to a federal agency and it can be read later by retailers, investors, and plaintiffs.
Attorney-directed work on what happened is, in many cases, protected by privilege in a way that a purely internal quality memo is not. That protection is not a reason to hide facts from FDA. It is a reason to sort the investigation, the legal risk, and the agency submission into separate workstreams before anyone writes “we violated.”
Our Warning Letter and Form 483 response work covers the observation-by-observation analysis, the corrective plan, the draft, confidentiality markings, and follow-up with the agency. If you want a written response reviewed against the 15-business-day clock, send the Form 483 as soon as you have it.
After you submit
Keep the evidence that matches every sentence in the letter. If FDA inspects again, investigators will ask to see the training, the revised method, and the batches released under the new control. Calendar each promised date and send the update without waiting to be asked.
If a Warning Letter still issues, read it against your Form 483 response. FDA often explains which corrections it accepted and which it did not. The next letter has to close those gaps, not repeat the last submission. The public letter also creates commercial issues, including customer questions and, in some cases, lawsuits that quote it. Those are reasons to be precise now, while the record is still an inspection file rather than a posted letter.
Questions companies ask after an inspection
Is a Form 483 the same as a Warning Letter?
No. A Form 483 is the investigator’s list of observations at the end of an inspection. A Warning Letter is a later agency notice that FDA believes significant violations occurred. The Form 483 response is your best chance to address the observations before that notice.
Do I have to respond to an FDA 483?
No statute sets a mandatory answer date for a Form 483. FDA’s practice is to review a response received within 15 business days before it decides on further action, and not to hold that decision for a late response. For an observation that matters, silence is a choice to let the inspection record stand alone.
Are Form 483s public?
FDA does not post them the way it posts Warning Letters. They can be released under FOIA, sometimes with company names and observations intact. Write the response as if a customer or a competitor may eventually read it.
What if we need more than 15 business days?
Submit the response anyway. Describe completed work, interim controls, and the dates for the rest. Do not wait until the work is finished and miss the review window.